Parathyroid hormone (PTH) is secreted by the parathyroid glands and is a systemic hormone which regulates calcium and phosphate homeostasis. PTH-related peptide (PTHrP) has considerable N-terminus homology to PTH (Goltzman et al., 1989; Martin and Suva, 1989) , stimulates bone resorption in vitro (Evely et al., 1990 ) and in vivo (Horiuchi et al., 1987) and is known to mediate humoral hypercalcaemia of malignancy (Broadus et al., 1988) . Initially identified in tumour cells (Burtis et al., 1987; Moseley et al., 1987; Stewart et al., 1987; Strewler et al., 1987) , PTHrP has now been localised in several normal tissues and a range of fetal tissues and, although the role of PTHrP has yet to be fully elucidated, it probably acts as a paracrine/autocrine regulator of cell function.
PTH and PTHrP exert their effects through cell-surface receptors which were originally thought to be principally in kidney and bone. Binding of the ligand to the receptor has multiple effects, including elevation of intracellular cAMP (Chase et al., 1969) , [Ca2+] (Donahue et al., 1988; Schoefl et al., 1991) and inositol phosphates (Cosman et al., 1989) . Expression cloning has identified a single PTH/PTHrP receptor, which binds both PTH and PTHrP at high affinity (Abou-Samra et al., 1992) . In rat, transcripts for this receptor have been identified in bone and kidney but also in many other tissues, including breast (Urena et al., 1993) . It has therefore been proposed that this single receptor species mediates many of the physiologically diverse actions of PTH PTHrP throughout the body.
PTHrP can be identified in normal lactating mammary tissue (Thiede and Rodan, 1988) and has been detected in primary cultures of mammary epithelial cells (Ferrari et al., 1992) . In transgenic mice which overexpress human PTHrP there is profound breast hypoplasia, suggesting an important role for PTHrP in the regulation of mammogenesis (Wysolmerski et al., 1993) . The peptide has been isolated from a mammary tumour (Burtis et al., 1987; Stewart et al., 1987) and identified in cultures of breast cancer cells (Walsh et al., 1992; Francini et al., 1993 (Southby et al., 1990) . In addition, immunocytochemistry (Bundred et al., 1991; Powell et al., 1991) and in situ hybridisation (Vargas et al., 1992) have revealed that a significant number of skeletal metastases arising from breast carcinoma express PTHrP. We have demonstrated that the human breast cancer cell line Hs578T produces PTHrP, while MCF-7 cells do not (Walsh et al., 1992) . Furthermore, transcripts for PTHrP have been detected in a primary human cell line, 8701 BC, which was isolated from a primary ductal infiltrating carcinoma of the breast (Luparello et al., 1993) . These findings indicate that PTHrP expression by breast cancer cells may play an important role in progression of the tumour. Expression of the PTH/MTHrP receptor may confer autocrine/paracrine regulation of the breast tumour cells by PTHrP. In this study we have investigated the expression of the PTH/PTHrP receptor by human breast cancer cell lines.
Materals and methods
Cell culture ZR-75-1, T-47-D, SK-BR-3, MDA-MB231 (all gifts from Professor P Rudland, Department of Biochemistry, University of Liverpool, UK), MCF-7 (a gift from Dr C Green, Department of Biochemistry, University of Liverpool, UK) and Hs578T (from ECACC, Porton Down, UK) and the human osteosarcoma cell line, Saos-2 (a gift from Dr J Beresford, Bath Institute of Rheumatic Diseases, UK) were grown in minimum essential medium (DMEM) supplemented with 10% fetal calf serum (FCS) (Sera Lab), 2 mM Lglutamine (Gibco) and antibiotics (100 U ml-' penicillin, 100 ;Lg ml-' streptomycin) (Gibco). sham cell proliferation kit (Amersham, UK). PTHrP (100ngml-') was added to serum-free cukures of MCF-7 cells. After 20 h incubation at 37C bromodeoxyuridine labelling reagent was added. After a further 4 h incubation the medium was removed from the dishes and the cell layers were fixed in 90% ethanol/10% acetic acid. Immunocytochemical detection of BrdU was then carried out using mouse anti-BrdU followed by horseradish peroxidasecoupled rat anti-mouse immunoglobulin and 2,3-diaminobenzidine as substrate. The dishes were examined microscopically and the percentage of dark-sning nuclei recorded in each field. Three wells were used for each treatment and ten fields examined in each well.
Measurement of intracellular cyclic AMP levels
The cell line(s) to be investigated were seeded in DMEM/ 10% FCS in six-well plates and grown to confluence. The medium was then roved and replaced with serum-free DMEM containing the phosphodiesterase inhibitor IILM 3-isobutyl-l-methyl-xanthine (IBMX) (Sigma) and PTHrP as appropriate. After 20 mm incubation with or without PTHrP, the medium was removed and 0.5 ml of 60% ethanol added to each well. The cell layer was scraped into the ethanol with a plastic transfer pipette and transferred to a 1.5 ml Eppendorf tube. The sample was then acetylated and cAMP level measured by competitive radioimmunoassay as previously described (O'Reilly et al., 1986) . The breast cancer cell lines were also investigated for the expression of PTHrP mRNA. RT-PCR identified specific 535 bp products in Saos-2, MCF-7, ZR-75-1, T47-D and Hs578T cells (Figure 3a) , which was confirmed by Southern blot analysis (Figure 3b ). (Figure 7) . In experiments with Hs578T cells (data not shown) there was no significant change in the concentrations of intracellular cAMP. (0) PTHrP have been shown to stimulate the production of matrix-degrading enzymes, including plasminogen activator (PA), in other cell types (Hamilton et al., 1984) . If PA production was linked to PTH/PTHrP receptor activation in breast cancer cells this would have major implications for metastasis. In addition, other work has shown that PTHrP expression by cells is stimulated by an extracellular matrix produced by bone cells (Guise et al., 1994. PTHfPTHrP receptor transcripts have an apparent widespread tissue distribution (Urena et al., 1993) , and we have shown that breast cancer cells express the receptor and respond to PTH/PTHrP. There is some evidence that primary hyperparathyroidism can be associated with increased incidence of malignancies (Farr et al., 1973) . A mitogenic effect of PTH on cancer cells could be one mechanism to explain this observation, but further work is required to confirm this.
Statistical aalysis
Subclones of the 8701 BC primary breast cancer cell line can be subdivided according to their ability to express PTHrP mRNA, with PTHrP-positive clones displaying a more aggressive growth behaviour than PTHrP-negative clones in vitro (Luparello et al., 1993) . In addition, an RT-PCR study of 38 normocalcaemic breast cancer patients with long-term follow-up demonstrated higher levels of PTHrP expression in patients who subsequently developed bone metastases (Bouizar et al., 1993) . In the data presented here we have shown the presence of PTHI-/PTHrP receptor mRNA in four out of six breast cancer cell lines, and one of these, MCF-7, was shown to proliferate in response to and PTHrP(1-34). We conclude that PTHrP may be an important autocrine/paracrine factor in the progression of breast cancer.
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